EVQLV is excited to announce we took first place in Columbia Engineering's Venture Competition (CVC). We've included a snippet from the announcement below. If you'd like to read the official release, you can do so here. In the Technology Challenge, avoMD and EVQLV...
The World Health Organization (WHO), yesterday, released a public statement for collaboration on COVID-19 treatment development of which Andrew Satz (CEO, EVQLV) gladly joined his name. Statement follows. We are scientists, physicians, funders and manufacturers who...
Our very own Brett Averso (CTO, EVQLV) was welcomed on the AI Podcast in 26.1 Minutes with hosts Brian Ray and Don Sheu. They discussed our work on COVID-19 with ImmunoPrecise, the benefits of a computational approach to antibody research and drug discovery, our...
Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV's optimism on the project. See below. Andrew Satz is the CEO and...
Our work with ImmunoPrecise on COVID-19 was covered by insideBIGDATA. They did a fantastic job covering the piece originally published by Columbia Data Science Institute, highlighting a few choice gems. See below. What our algorithms do is reduce the likelihood of...
Columbia Data Science Institute recently covered EVQLV's work towards developing therapeutic candidates against COVID-19 with Immunoprecise Antibodies. See below. Two graduates of the Data Science Institute (DSI) at Columbia University are using computational design...